Last week, the Centers for Medicare & Medicaid Services (CMS) released its 713-page proposed policy changes and updates for the Medicare program. See the links below. Buried in this document is a radical concept: Part D plans would be required to recognize the value of manufacturer rebates and pharmacy payments in retail prescription prices. Show More Summary
CBI’s 13th Trade and Channel Strategies December 11-12, 2017 | Philadelphia, PAwww.cbinet.com/trade This December 11-12 in Philadelphia, join stakeholders from across the life science industry for in-depth education on trade and channel strategy management. Show More Summary
We have no sooner gotten rid of the candy from Halloween then we are preparing to receive our Thanksgiving guests and putting together menus for the big day, only to rush headlong into the next holiday season that will involve … Continue reading ?
The National Pharmaceutical Council (NPC) recently released Toward Better Value, a fascinating survey of employers’ views about their pharmacy benefit managers (PBMs). (free download) According to the results, employers are unhappy with PBMs’ performance on crucial services. Show More Summary
There has been a huge push in policy circles to speed innovation in medicine which is manifest in several initiatives, including most notably the 21st Century Cures Act implementation. But it would be a mistake to assess the quickening pace … Continue reading ?
The editors of PLOS Medicine announce a forthcoming special issue devoted to the health impacts of climate change. Research submissions are now being invited, with a deadline of February 2nd, 2018 Climate change and the impacts
Specialty Pharmacy’s New Frontier: How to Deliver and Document Therapy OutcomesA free webinar hosted by Therigy Wednesday, December 13, 1pm-2pm ESTRegister here. Therigy is pleased to announce a free webinar exploring therapy outcomes on Wednesday, December 13, 1pm-2pm EST. Show More Summary
A few weeks ago, I highlighted the latest drug spending data in Reality Check: New Prime Therapeutics Data Show Very Low Drug Spending Growth in 2017. As I see it, these data contradict the public rhetoric about excessive growth in drug spending and prices. Show More Summary
Phew – candy handed out and leftovers gobbled up at the office. I am safe. Now comes the rather heavy preparation for Thanksgiving to receive guests and prepare feasts. That, combined with extreme business foreclosed an intermediate posting this week … Continue reading ?
In a previous analysis (Employer Pharmacy Benefits in 2017: More Cost-Shifting to Patients As Tiers and Coinsurance Expand), I examined the structure of employers’ 2017 pharmacy benefit plans. Today, I examine the growing role of deductibles. Show More Summary
Senior Editor Richard Turner discusses the content published in week 1 of the PLOS Medicine Special Issue on HIV/AIDS. This week, PLOS Medicine begins publication of a Special Issue on Advances in HIV Prevention, Treatment
It’s time for our annual analysis of the Kaiser/HRET 2017 Employer Health Benefits Survey, which you can read online for free. The survey delves into employer-sponsored health coverage at more than 2,000 companies. In the charts below,...Show More Summary
CBI’s 15th Specialty Therapies – A Forum for PayersJanuary 25-26, 2018 | Las Vegas, NVwww.cbinet.com/specialtytherapiesCBI announces that registration is open for the Specialty Therapies Forum!Join stakeholders from across the healthcare...Show More Summary
We are finally about to Fall Backward! Don’t forget to set your clock back this weekend to mark the end of Daylight Savings Time as we once again return to dark early evenings and even in December – dark late … Continue reading ?
Speculation about Amazon’s intentions for the drug channel has reached a new high. Below, I briefly review the recent news and hype. Amid the hubbub, you may have missed intriguing comments from Tim Wentworth, president and CEO of the pharmacy benefit manager (PBM) Express Scripts. Show More Summary
That's one question on the mind of EyeOnFDA author Mark Senak of FleishmanHillard's Washington, D.C. office. Senak plotted the number of "Action Letters," which are Warning Letters to drug company CEOs plus so-called "untitled" letters addressed to underlings - usually regulatory officers. Show More Summary
The Office of Prescription Drug Promotion (OPDP), once known as the Division for Drug Marketing, Advertisting and Communications (DDMAC) monitors company communications about medical products and when it deems those communications have gone outside regulatory parameters, the office issues a … Continue reading ?
Eeek! Time for my Halloween roundup of Drug Channels news stories. In this issue: Spooktakular! An FTC competition workshop will include a terrifying panel on pharmacy benefit managers (PBMs) Scary! The pros and cons of frightful high-deductible...Show More Summary
CBI’s Drug Pricing Transparency CongressDecember 5, 2017 | Philadelphia, PAwww.cbinet.com/drugpricingWith numerous states across the country ramping up on introducing and passing laws aimed at drug pricing transparency and reporting,...Show More Summary
You can't make this stuff up! According to Huffington Post, "Pharmaceutical sales representatives selling an opioid-based drug 50 times more powerful than heroin filmed a company-made rap video in which they danced with a giant bottle...Show More Summary